1. Medtech Insight
  2. >>Business

Sinclair Pharma Bullish About Profitability By Year-End

 
• By Catherine Longworth

Encouraged by its solid sales performance in the first half of this year, UK aesthetics company Sinclair Pharma is optimistic it can close out 2017 with a small profit. The firm's H1 revenues were boosted by continued growth in key markets, leading to a 16% top-line growth.

UK aesthetics company Sinclair Pharma PLC is confident that it will be in the black by the end of the year, delivering an adjusted EBITDA profit for fiscal 2017. The London AIM-listed company's bullishness comes from a solid performance for the first-half, in which it reported revenue of £20.1m ($27.2m), a 16% rise from the £17.3m recorded in the same period last year. Driving this growth were sales of the company's key brands of aesthetic products – Silhouette Soft, InstaLift, Ellansé and Perfectha – which increased 17% on a constant currency basis.

Alan Olby, Sinclair Pharma CFO, told Medtech Insight that in spite of the different timing in stocking by a major distributor in South Korea, which dampened reported sales, the overall...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

 
• By Shubham Singh

Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.

FDA Halts Acceptance Of Chinese Lab Data Due To Accuracy Issues

 
• By Elizabeth Orr

The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.